Clinical Focus ›› 2023, Vol. 38 ›› Issue (12): 1140-1145.doi: 10.3969/j.issn.1004-583X.2023.12.015
Previous Articles Next Articles
-
Received:2023-10-17Online:2023-12-20Published:2024-01-30
CLC Number:
Cite this article
share this article
Add to citation manager EndNote|Ris|BibTeX
URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2023.12.015
| [1] |
Li J, Van d WDE, Zhu G, et al. Desialylation is a mechanism of fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia[J]. Nat Commun, 2015, 6:7737.
doi: 10.1038/ncomms8737 pmid: 26185093 |
| [2] |
Makar RS, Zhukov OS, Sahud MA, et al. Thrombopoietin levels in patients with disorders of platelet production: Diagnostic potential and utility in predicting response to TPO Receptor agonists[J]. Am J Hematol, 2013, 88(12):1041-1044.
doi: 10.1002/ajh.23562 pmid: 23913253 |
| [3] |
Yang L, Wang L, Zhao CH, et al. Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia[J]. Blood, 2010, 116(20):4307.
doi: 10.1182/blood-2010-02-267435 pmid: 20671119 |
| [4] |
Semple JW, Rebetz J, Maouia A, et al. An update on the pathophysiology of immune thrombocytopenia[J]. Curr Opin Hematol, 2020, 27(6):423-429.
doi: 10.1097/MOH.0000000000000612 pmid: 32868673 |
| [5] |
Miltiadous O, Hou M, Bussel JB. Identifying and treating refractory itp: Difficulty in diagnosis and role of combination treatment[J]. Blood, 2019, 135(7): 472-490.
doi: 10.1182/blood.2019003599 URL |
| [6] |
Vianelli N, Auteri G, Buccisano F, et al. Refractory primary immune thrombocytopenia (ITP): Current clinical challenges and therapeutic perspectives[J]. Ann Hematol, 2022, 101(5):963-978.
doi: 10.1007/s00277-022-04786-y pmid: 35201417 |
| [7] |
Rodeghiero F. A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP[J]. Br J Haematol, 2018, 181(2):183-195.
doi: 10.1111/bjh.2018.181.issue-2 URL |
| [8] |
Patel VL, Mahévas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia[J]. Blood, 2012, 119 (25): 5989-5995.
doi: 10.1182/blood-2011-11-393975 pmid: 22566601 |
| [9] |
Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia[J]. Blood Adv, 2019, 3(22):3780-3817.
doi: 10.1182/bloodadvances.2019000812 pmid: 31770441 |
| [10] | 侯明, 胡豫. 成人原发免疫性血小板减少症诊断与治疗中国指南(2020年版)[J]. 中华血液学杂志, 2020, 41(8):617-623. |
| [11] |
Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists[J]. Int J Hematol, 2013, 98(1):10-23.
doi: 10.1007/s12185-013-1382-0 pmid: 23821332 |
| [12] |
Erickson-Miller CL, Delorme E, Tian SS, et al. Preclinical activity of eltrombopag (sb-497115), an oral, nonpeptide thrombopoietin receptor agonist[J]. Stem Cells, 2008, 27(2):424-430.
doi: 10.1634/stemcells.2008-0366 URL |
| [13] |
Broudy VC, Lin NL. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl[J]. Cytokine, 2004, 25(2):52-60.
pmid: 14693160 |
| [14] |
Ghanima W, Cooper N, Rodeghiero F, et al. Thrombopoietin receptor agonists: Ten years later[J]. Haematologica, 2019, 104(6):1112-1123.
doi: 10.3324/haematol.2018.212845 pmid: 31073079 |
| [15] |
Will B, Kawahara M, Luciano JP, et al. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome[J]. Blood, 2009, 114(18):3899-3908.
doi: 10.1182/blood-2009-04-219493 pmid: 19710504 |
| [16] |
Chen LY. Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis[J]. Stem Cell Res, 2012, 9(2):77-86.
doi: 10.1016/j.scr.2012.05.001 pmid: 22683680 |
| [17] |
Di Buduo CA, Currao M, Pecci A, et al. Revealing eltrombopag's promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation[J]. Haematologica, 2016, 101(12):1479-1488.
pmid: 27515246 |
| [18] |
Bao W, Bussel JB, Heck S, et al. Improved regulatory t-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents[J]. Blood, 2010, 116(22):4639-4645.
doi: 10.1182/blood-2010-04-281717 pmid: 20688957 |
| [19] |
Zufferey A, Kapur R, Semple JW. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)[J]. J Clin Med, 2017, 6(2):16.
doi: 10.3390/jcm6020016 URL |
| [20] | Liu XG, Liu S, Feng Q, et al. Thrombopoietin receptor agonists shift the balance of Fcγ receptors toward inhibitory receptor IIb on monocytes in ITP[J]. Blood, 2016, 128(6):852-861. |
| [21] |
Yang F, Zong H, Li F, et al. Eltrombopag modulates the phenotypic evolution and potential immunomodulatory roles of monocytes/macrophages in immune thrombocytopenia[J]. Platelets, 2023, 34(1): 2135694.
doi: 10.1080/09537104.2022.2135694 URL |
| [22] |
Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial[J]. Lancet, 2015, 371(9610):395-403.
doi: 10.1016/S0140-6736(08)60203-2 URL |
| [23] |
Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia[J]. N Engl J Med, 2010, 363(20):1889-1899.
doi: 10.1056/NEJMoa1002625 URL |
| [24] |
Bussel JB, Kuter DJ, Pullarkat V, et al. Safety and efficacy of long-term treatment withromiplostim in thrombocytopenic patients with chronic ITP[J]. Blood, 2009, 113(10):2161-2171.
doi: 10.1182/blood-2008-04-150078 pmid: 18981291 |
| [25] |
Kuter DJ, Bussel JB, Newland A, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: Safety and efficacy[J]. Br J Haematol, 2013, 161(03):411-423.
doi: 10.1111/bjh.2013.161.issue-3 URL |
| [26] |
Wang L, Gao Z, Chen XP, et al. Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: A systematic review and metaanalysis[J]. Sci Rep, 2016, 6(1): 39003.
doi: 10.1038/srep39003 |
| [27] |
Hayes S, Ouellet D, Zhang J, et al. Population PK/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosing[J]. J Clin Pharmacol, 2013, 51(10):1403-1417.
doi: 10.1177/0091270010383019 URL |
| [28] |
Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: A randomised, double-blind, placebo-controlled trial[J]. Lancet, 2009, 373(9664):641-648.
doi: 10.1016/S0140-6736(09)60402-5 pmid: 19231632 |
| [29] |
Gregory C. Eltrombopag for the treatment of immune thrombocytopenia[J]. Expert Rev Hematol, 2011, 4(3):261-269.
doi: 10.1586/ehm.11.25 pmid: 21671710 |
| [30] |
Wong RSM, Saleh MN, Khelif A, et al. Safety and efficacy of longterm treatment of chronic/persistent ITP with eltrombopag: Final results of the EXTEND study[J]. Blood, 2017, 130(23):2527-2536.
doi: 10.1182/blood-2017-04-748707 URL |
| [31] |
Yang R, Li J, Jin J, et al. Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia[J]. Br J Haematol, 2017, 176(01):101-110.
doi: 10.1111/bjh.2017.176.issue-1 URL |
| [32] |
Bussel JB, Kuter DJ, Aledort LM, et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia[J]. Blood, 2014, 123(25):3887-3894.
doi: 10.1182/blood-2013-07-514398 pmid: 24802775 |
| [33] |
Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia[J]. Br J Haematol, 2018, 183(3):479-490.
doi: 10.1111/bjh.2018.183.issue-3 URL |
| [34] |
Mei H, Zhou H, Hou M, et al. Avatrombopag for adult chronic primary immune thrombocytopenia: A randomized phase 3 trial in China[J]. Res Pract Thromb Haemost, 2023, 7(6):102158.
doi: 10.1016/j.rpth.2023.102158 URL |
| [35] |
Xie C, Zhao H, Bao X, et al. Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist[J]. J Cell Mol Med, 2018, 22(11):5367-5377.
doi: 10.1111/jcmm.13809 pmid: 30156363 |
| [36] |
Mei H, Liu X, Li Y, et al. A multicenter, randomized phase III trial of hetrombopag: A novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia[J]. J Hematol Oncol, 2021, 14(1):37.
doi: 10.1186/s13045-021-01047-9 |
| [37] |
Hidaka H, Kurosaki M, Tanaka H, et al. Lusutrombopag reduces need for platelet transfusion in patients with thrombocytopenia undergoing invasive procedures[J]. Clin Gastroenterol Hepatol, 2019, 17(6): 1192-1200.
doi: 10.1016/j.cgh.2018.11.047 URL |
| [38] |
Peck-Radosavljevic M, Simon K, Iacobellis A, et al. Lusutrombopag for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures (L-PLUS 2)[J]. Hepatology, 2019, 70(4): 1336-1348.
doi: 10.1002/hep.30561 pmid: 30762895 |
| [39] |
Ding Z, Wu H, Zeng Y, et al. Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures[J]. Hepatol Int, 2023, 17(1): 180-189.
doi: 10.1007/s12072-022-10421-9 |
| [40] |
Ebbo M, Rivière E, Godeau B. Adult immune thrombocytopenia and thrombopoietin receptor agonist: Ten years later[J]. Rev Med Interne, 2021, 42(1): 38-45.
doi: 10.1016/j.revmed.2020.05.017 pmid: 32712041 |
| [41] |
Neunert CE. Thrombopoietin receptor agonist use for immune thrombocytopaenia[J]. Hamostaseologie, 2019, 39(3): 272-278.
doi: 10.1055/s-0038-1676129 pmid: 30646404 |
| [42] |
Kuter DJ, Mufti GJ, Bain BJ, et al. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim[J]. Blood, 2009, 114(18): 3748-3756.
doi: 10.1182/blood-2009-05-224766 pmid: 19671919 |
| [43] |
Ghanima W, Geyer JT, Lee CS, et al. Bone marrow fibrosis in 66 Immune Thrombocytopenia patients treated with thrombopoietin receptor agonists: a single center long-term follow-up[J]. Haematologica, 2014, 99(5): 937-944.
doi: 10.3324/haematol.2013.098921 pmid: 24463212 |
| [44] |
Brynes RK, Wong RS, Thein MM, et al. A 2-Year, Longitudinal, Prospective study of the effects of eltrombopag on bone marrow in patients with chronic immune thrombocytopenia[J]. Acta Haematol, 2017, 137(2):66-72.
doi: 10.1159/000452992 URL |
| [45] |
Janssens A, Rodeghiero F, Anderson D, et al. Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia[J]. Ann Hematol, 2016, 95(7):1077-1087.
doi: 10.1007/s00277-016-2682-2 pmid: 27130310 |
| [46] |
Brynes RK, Orazi A, Theodore D, et al. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag:data from the EXTEND study[J]. Am J Hematol, 2015, 90(7):598-601.
doi: 10.1002/ajh.v90.7 URL |
| [47] |
Al-Samkari H, Kuter DJ. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia[J]. Am J Hematol, 2018, 93(12):1501-1508.
doi: 10.1002/ajh.25275 pmid: 30187942 |
| [48] |
Rodeghiero F. Is ITP a thrombophilic disorder?[J]. Am J Hematol, 2016, 91(1):39-45.
doi: 10.1002/ajh.24234 pmid: 26547507 |
| [49] |
Rottenstreich A, Kleinstern G, Spectre G, et al. Thromboembolic events following splenectomy: Risk factors, prevention, management and outcomes[J]. World J Surg, 2018, 42(3): 675-681.
doi: 10.1007/s00268-017-4185-2 pmid: 28808782 |
| [50] |
Weber E, Moulis G, Mahévas M, et al. Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study[J]. Rev Med Interne, 2017, 38(3): 167-175.
doi: S0248-8663(16)30555-0 pmid: 27793553 |
| [51] |
Rodeghiero F, Stasi R, Giagounidis A, et al. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: A pooled analysis of 13 clinical trials[J]. Eur J Haematol, 2013, 91(5):423-436.
doi: 10.1111/ejh.12181 pmid: 23927437 |
| [52] | Červinek L, Mayer J, Doubek M, et al. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults[J]. Doubek M, 2015, 102(1):7-11. |
| [53] |
Marshall AL, Scarpone R, De Greef M, et al. Remissions after long-term use of romiplostim for immune thrombocytopenia[J]. Haematologica, 2016, 101(12):e476-e478.
doi: 10.3324/haematol.2016.151886 URL |
| [54] |
Mazzucconi MG, Santoro C, Baldacci E, et al. TPO-RAs in pITP: Description of a case series and analysis of predictive factors for response[J]. Eur J Haematol, 2017, 98(3):242-249.
doi: 10.1111/ejh.12822 pmid: 27797414 |
| [55] |
Lozano ML, Mingot-Castellano ME, Perera MM, et al. Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia[J]. Sci Rep, 2019, 9(1):16680.
doi: 10.1038/s41598-019-53209-y pmid: 31723222 |
| [56] |
Iino M, Sakamoto Y, Sato T. Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice[J]. Int J Hematol, 2020, 112(2): 159-168.
doi: 10.1007/s12185-020-02893-y pmid: 32476083 |
| [57] |
Lucchini E, Palandri F, Volpetti S, et al. Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: Results of a phase II, multicentre, prospective study[J]. Br J Haematol, 2021, 193(2):386-396.
doi: 10.1111/bjh.v193.2 URL |
| [58] | Matzdorff A, Meyer O, Ostermann H, et al. Immune Thrombocytopenia-current diagnostics and therapy: Recommendations of a joint working group of DGHO, ÖGHO, SGH, GPOH, and DGTI[J]. Oncol Res Treat, 2018, 41(Suppl 5):1-30. |
| [59] |
Zaja F, Carpenedo M, Baratè C, et al. Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations[J]. Blood Rev, 2020, 41:100647.
doi: 10.1016/j.blre.2019.100647 URL |
| [60] |
Cuker A, Despotovic JM, Grace RF, et al. Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method[J]. Res Pract Thromb Haemost, 2021, 5(1): 69-80.
doi: 10.1002/rth2.12457 pmid: 33537531 |
| [61] |
Cooper N, Hill QA, Grainger J, et al. Tapering and discontinuation of thrombopoietin receptor agonist therapy in patients with immune thrombocytopenia: Results from a modified delphi panel[J]. Acta Haematol, 2021, 144(4):418-426.
doi: 10.1159/000510676 URL |
| [62] |
Roumier M, Le Burel S, Audia S, et al. High dose romiplostim as a rescue therapy for adults with severe bleeding and refractory immune thrombocytopenia[J]. Am J Hematol, 2021, 96(2):E43-E46.
doi: 10.1002/ajh.26040 pmid: 33125750 |
| [1] | Yang Jinqiang, Zhang Renmin. Prognostic value of procalcitonin to platelet ratio in patients with fever with thrombocytopenia syndrome [J]. Clinical Focus, 2023, 38(4): 346-351. |
| [2] | Wu Qiong, Sun Feng, Zhang Kai, Wang Zhiyi, Zhang Nana, Cheng Hui, Xiang Yang, Chang Xiaohui. Curative effect of combination of eltrombopag and low-dose prednisone on refractory and relapsed primary immune thrombocytopenia in elderly patients [J]. Clinical Focus, 2022, 37(11): 1008-1011. |
| [3] | . [J]. Clinical Focus, 2021, 36(12): 1139-1143. |
| [4] | Fu Haixia. Study on standardized diagnosis and treatment of primary immune thrombocytopenia [J]. Clinical Focus, 2021, 36(10): 896-900. |
| [5] | Wang Jing;Li Ruibin;Cui Wei. Analysis of characteristics and risk factors of acute serious thrombocytopenia associated with tirofiban in Chinese patients [J]. Clinical Focus, 2015, 30(4): 361-366. |
| [6] | PENG Jun. Advances in the treatment of refractory/relapsed immune thrombocytopenia [J]. Clinical Focus, 2014, 29(10): 1091-1094. |
| [7] | . [J]. CLINICAL FOCUS, 2013, 28(11): 1292-1293. |
| [8] | . [J]. Clinical Focus, 2012, 27(22): 0-0. |
| [9] | . [J]. Clinical Focus, 2012, 27(20): 1833-1836. |
| [10] | . [J]. Clinical Focus, 2012, 27(6): 547-0. |
| [11] | . [J]. CLINICAL FOCUS, 2011, 26(11): 984-985. |
| [12] | . [J]. CLINICAL FOCUS, 2011, 26(7): 604-605. |
| [13] | KONG Rong;QIU Hong-chun;WU Peng-fei;WANG Yong. Significance of bone marrow megakaryocyte counts and platelet parameters in patients with idiopathic thrombocytopenic purpura [J]. CLINICAL FOCUS, 2011, 26(2): 104-107. |
| [14] | . [J]. CLINICAL FOCUS, 2010, 25(20): 1815-1816. |
| [15] | . [J]. CLINICAL FOCUS, 2010, 25(4): 359-361. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||